Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hypertension 1Hot Flashes 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

relacorilant 5Nutrition Assessment 4Hydrochlorothiazide 3Amlodipine 3aliskiren 2Osilodrostat 2Lisinopril 2Bevacizumab 2Adrenalectomy 2sacubitril and valsartan sodium hydrate drug combination 1pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1ganirelix 1gallium Ga 68 dotatate 1fimasartan 1enzalutamide 1clevidipine 1cediranib 1bicalutamide 1benazepril 1Vitamin D 1Tumor Necrosis Factors 1Thiazides 1Therapeutics 1Surveys and Questionnaires 1Sulindac 1Sodium Chloride 1Resistance Training 1Receptors, Androgen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypertension × Desvenlafaxine Succinate × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡